Repeated low-level red-light therapy for at least 1 year is associated with reduced cone density near the retinal fovea in ...

Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that ...

Researchers unveil a groundbreaking method to stimulate retinal M cells, creating a new color, "olo," beyond human vision's ...

DURHAM, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness ...

Cost-effectiveness watchdog NICE has recommended Lytenava as an option for wet AMD in adults who have signs of recent disease progression, no permanent structural damage to the central fovea ...

Gold particles could help reproduce the visual signals of damaged photoreceptor cells and restore vision, according to new ...

causing blurry vision, blind spots, and in advanced stages, total loss of central vision. These photoreceptors come in the form of "cone" cells responsible for our perception of color ...

Advancements like SLT (selective laser trabeculoplasty) have reshaped glaucoma treatment, improving patient outcomes compared ...